News Story: Full Text
Sponsored By
Orbus Therapeutics Inc Clinical Trial for Recurrent Anaplastic Astrocytomas
Please Click On The Above Banner For More Details
Braintumor Website


YM BioSciences Drug Is Given Orphan Status

Posted on: 12/01/2004

YM BioSciences Drug Is Given Orphan Status

Associated Press
11.30.2004, 09:06 AM

YM BioSciences Inc. on Tuesday said the Food and Drug Administration has given an orphan-drug designation to its experimental drug for treating patients with brain cancer.

Orphan-drug status gives Ontario, Canada-based YM a seven-year exclusivity period, potential tax breaks, possible funding and assistance with clinical trials while the company develops its drug, TheraCIM hR3, to treat a rare condition that affects fewer than 200,000 people in the United States.

TheraCIM, which has already been designated an orphan drug by European regulators, is currently undergoing two mid-stage trials in Europe and is expected to begin late-stage testing early next year.

YM said its European licensee, Oncoscience AG, anticipates launching a late-stage trial of TheraCIM in adults with glioma, or brain cancer, in early 2005.

The drug, a monoclonal antibody that targets the epidermal growth factor receptor, has been shown to double a patient's response to chemotherapy in mid-stage trials of patients with head and neck cancer, the company said

Click HERE to return to brain tumor news headlines

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557